Otonomy ’s Phase III trial for M é ni è re's disease fails to meet endpoints

US-based Otonomy has reported results from a Phase III clinical trial (AVERTS-1) of its drug candidate Otividex (OTO-104) to treat patients with a chronic ear disorder called Unilateral M é ni è re ’s disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news